Published in TB and Outbreaks Week, July 29th, 2008
Vical's Vice President of Vaccine Research, Larry R. Smith, Ph.D., will present preliminary safety and immunogenicity results from this first human trial of vaccines formulated with the company's patented Vaxfectin(R) adjuvant. Results from this trial will drive the next steps in the company's H5N1 pandemic influenza vaccine program and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week